Search
Search Results for: ExaMD
ExaWizards and ExaMD Present Findings from a Wearable Device Study on Breast Cancer Patients—A Joint Research Project with Kansai Medical University, Daiichi Sankyo, and Others—at the American Society of Clinical Oncology “ASCO 2026” ‐Aiming to develop new digital AI healthcare services based on the analysis results‐
ExaWizards Inc. (Minato-ku, Tokyo; Representative Director, President & CEO : Makoto Haruta; hereinafter “ […]
ExaMD, an ExaWizards Group Company, Submits a Clinical Trial Notification for an AI-Powered Cognitive Function Diagnostic Support Application — Entering the Final Stages of Regulatory Approval Aiming for Early Approval within FY3/2027 Through an Innovative and Efficient Clinical Trial —
ExaMD Inc. (Minato-ku, Tokyo; Representative Director, Koji Hazama; hereafter, “ExaMD”), a group company of Ex […]
ExaMD, an ExaWizards Group Company, and EPS Group Establish Medical Device Industry’s First*¹ Value Chain for SaMD, from Clinical Development to Sales — Scheme to be Implemented for Medical AI Gait Analysis App “LocoStep” to Accelerate Future SaMD Sales —
ExaMD Inc. (Minato-ku, Tokyo; Representative Director, Koji Hazama; hereafter, “ExaMD”), a group company of Ex […]
ExaMD, a Member of the ExaWizards Group, Research and Development of Dementia Diagnosis SaMD Published in International Medical Journal “PLOS ONE” – High-precision and energy-saving AI model can be installed on smartphones, under development with priority review designation from the Ministry of Health, Labour and Welfare –
ExaMD Inc. (Minato-ku, Tokyo, Representative Director: Koji Hazama; hereinafter, “ExaMD”), a member of the Exa […]
ExaMD, a Member of the ExaWizards Group, Partners with EPS Group Launching Accelerated Clinical Development for Diagnostic SaMD Commercialization — Proprietary Algorithm Incorporating On-Site Expertise Achieves Up to 40% Reduction in Planning Time, Is Expected to Cut Annual Operating Costs by Several Hundred Million Yen —
ExaMD Inc. (Minato-ku, Tokyo, Representative Director: Koji Hazama; hereinafter, “ExaMD”), a member of the Exa […]
ExaMD, a Member of the ExaWizards Group, Launches a Gait Analysis AI Application for Medical Institutions — Simplifying Gait Function Visualization with a Smartphone, Collaborative Development with Juntendo University —
ExaMD Inc. (Minato-ku, Tokyo, Representative Director: Koji Hazama; hereinafter, “ExaMD”), a member of the Exa […]
ExaMD, a Member of the ExaWizards Group, obtained the Type II Medical Device Manufacturing and Marketing License, and the Medical Device Sales License – Empowering ExaMD to Develop, Manufacture, and Market Software as a Medical Device (SaMD) –
ExaMD Inc. (Minato-ku, Tokyo, Representative Director: Koji Hazama; hereinafter, “ExaMD”), a subsidiary of Exa […]
ExaWizards’ Wholly Owned Subsidiary, ExaMD AI-Powered Dementia Diagnosis App Using Conversational Audio Designated as a Priority Review Product under Innovative Medical Device Program
ExaWizards Inc. (Minato-ku, Tokyo, Representative Director & President: Makoto Haruta; hereinafter, “ExaWi […]
ExaWizards’ Wholly Owned Subsidary, ExaMD AI-Powered Dementia Diagnosis App Using Conversational Audio Gained Consensus on Priority Review Designation under Innovative Medical Device Program ~Simple smartphone app that takes a minute to use, aiming for world-first approval as a diagnostic medical device ~
We, ExaWizards Inc. (Minato-ku, Tokyo, Representative Director & President: Makoto Haruta; hereinafter, “E […]
ExaMD, a Subsidiary of ExaWizards Group, Partners with EPNextS to Develop Digital Services
– Leveraging Expertise in Drug Development Support for Clinical Research and Development in AI Biomarker-Compatible Solutions –
ExaMD Inc., a fully-owned subsidiary of ExaWizards Inc. (Minato-ku, Tokyo, Representative Director & Presi […]